Literature DB >> 29875219

Autoimmune pancerebellitis associated with pembrolizumab therapy.

Jeffrey R Vitt1, Collin Kreple2, Nausheen Mahmood2, Elliot Dickerson2, Giselle Y Lopez2, Megan B Richie2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29875219      PMCID： PMC6053111          DOI： 10.1212/WNL.0000000000005781

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  7 in total

1.  Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.

Authors:  Tanya J Williams; David R Benavides; Kelly-Ann Patrice; Josep O Dalmau; Alexandre Leon Ribeiro de Ávila; Dung T Le; Evan J Lipson; John C Probasco; Ellen M Mowry
Journal:  JAMA Neurol       Date:  2016-08-01       Impact factor: 18.302

Review 2.  Infections of the cerebellum.

Authors:  Amy A Pruitt
Journal:  Neurol Clin       Date:  2014-10-24       Impact factor: 3.806

Review 3.  Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature.

Authors:  L Spain; G Walls; M Julve; K O'Meara; T Schmid; E Kalaitzaki; S Turajlic; M Gore; J Rees; J Larkin
Journal:  Ann Oncol       Date:  2017-02-01       Impact factor: 32.976

4.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

Authors:  Tanguy Y Seiwert; Barbara Burtness; Ranee Mehra; Jared Weiss; Raanan Berger; Joseph Paul Eder; Karl Heath; Terrill McClanahan; Jared Lunceford; Christine Gause; Jonathan D Cheng; Laura Q Chow
Journal:  Lancet Oncol       Date:  2016-05-27       Impact factor: 41.316

5.  Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.

Authors:  Justin C Kao; Bing Liao; Svetomir N Markovic; Christopher J Klein; Elie Naddaf; Nathan P Staff; Teerin Liewluck; Julie E Hammack; Paola Sandroni; Heidi Finnes; Michelle L Mauermann
Journal:  JAMA Neurol       Date:  2017-10-01       Impact factor: 18.302

Review 6.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

Authors:  J Naidoo; D B Page; B T Li; L C Connell; K Schindler; M E Lacouture; M A Postow; J D Wolchok
Journal:  Ann Oncol       Date:  2015-09-14       Impact factor: 32.976

Review 7.  Disorders of the cerebellum: ataxia, dysmetria of thought, and the cerebellar cognitive affective syndrome.

Authors:  Jeremy D Schmahmann
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2004       Impact factor: 2.198
  7 in total
  8 in total

Review 1.  Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.

Authors:  Peter Chei-Way Pan; Aya Haggiagi
Journal:  Curr Oncol Rep       Date:  2019-11-27       Impact factor: 5.075

Review 2.  Neurologic complications of immune checkpoint inhibitors.

Authors:  Alexandra M Haugh; John C Probasco; Douglas B Johnson
Journal:  Expert Opin Drug Saf       Date:  2020-03-11       Impact factor: 4.250

Review 3.  Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses.

Authors:  Sergio Muñiz-Castrillo; Alberto Vogrig; Nicolás Lundahl Ciano-Petersen; Macarena Villagrán-García; Bastien Joubert; Jérôme Honnorat
Journal:  Cerebellum       Date:  2022-01-12       Impact factor: 3.648

Review 4.  A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors.

Authors:  Neeraj Chhabra; Joseph Kennedy
Journal:  J Med Toxicol       Date:  2021-04-07

5.  Pembrolizumab-Related Side Effects: Acute Renal Failure and Severe Neurological Toxicity.

Authors:  Gabriele Fasano; Ingrid Marcela Pabon; Yaroslava Longhitano; Christian Zanza; Graziano Carlidi; Enrico Ravera; Andrea Della Selva
Journal:  Medicina (Kaunas)       Date:  2022-01-30       Impact factor: 2.430

Review 6.  Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review.

Authors:  Simon Nannini; Larysa Koshenkova; Seyyid Baloglu; Dominique Chaussemy; Georges Noël; Roland Schott
Journal:  J Neurooncol       Date:  2022-04-13       Impact factor: 4.506

7.  Challenges of New Approaches in Metastatic Merkel Cell Carcinoma.

Authors:  Ana Monteiro; Emanuel Gouveia; Daniela Garcez; Sara Donato; Diogo Martins-Branco; Joana Marques; Hugo Nunes; Maria José Passos; Ana Isabel Clara; António Moreira
Journal:  Case Rep Oncol       Date:  2020-05-12

8.  Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization.

Authors:  Hans Urban; Eike Steidl; Elke Hattingen; Katharina Filipski; Markus Meissner; Martin Sebastian; Agnes Koch; Adam Strzelczyk; Marie-Thérèse Forster; Peter Baumgarten; Michael W Ronellenfitsch; Joachim P Steinbach; Martin Voss
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.